BioCryst Announces Approval of ORLADEYO® for Pediatric HAE Patients in Japan
— Expands availability of the first and only oral prophylactic therapy for patients with HAE ages 2 to <12 years in Japan —
Covered in this story
Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.